Genital herpes

Lore & Background

Genital herpes is caused by two types of herpes simplex virus: HSV-1 and HSV-2. Historically, HSV-2 was more common, but genital HSV-1 has become more prevalent in the developed world. Symptoms typically appear about 4 days after exposure and can last up to 4 weeks, including small blisters that become painful ulcers, along with fever, aching, or swollen lymph nodes. After the initial outbreak, further outbreaks may occur but are generally milder; recurrence is more frequent with HSV-2 (about four to six times per year) than with HSV-1 (about once per year).

Reader's Guide

Genital herpes remains a significant global health concern due to its high prevalence and lack of a cure. In 2015, about 846 million people were infected worldwide, with a 51.97% increase in cases between 1990 and 2021. The infection is often asymptomatic, contributing to its spread, as many individuals are unaware they carry the virus. Prevention strategies include condom use, reducing the number of sexual partners, and suppressive antiviral therapy, which can reduce transmission by up to 90%. Complications, though rare, include aseptic meningitis, increased risk of HIV/AIDS if exposed, and neonatal herpes during childbirth. The disease disproportionately affects women and has seen declining rates of HSV-2 in the United States between 1990 and 2010, though prevalence remains high in regions like Southern Sub-Saharan Africa.

Did You Know?

• Most people with genital herpes have no or mild symptoms and do not know they are infected.
• The risk of transmission between a couple over a year is about 7.5% for unprotected sex.
• Suppressive antiviral therapy can reduce transmission risk by 90%.
• Fewer than 0.1% of babies born to mothers with genital herpes get neonatal herpes.

The Clinical Landscape: From First Blister to Long-Term Recurrence

Genital herpes often announces itself quietly. Many infected individuals never develop noticeable symptoms, while others experience small blisters that rupture into painful open sores, accompanied by fever, body aches, and swollen lymph nodes. Symptoms typically emerge roughly four days after exposure and can persist for as long as four weeks. In men, lesions appear on the glans, shaft, inner thigh, buttocks, or anus; in women, they cluster around the pubis, clitoris, vulva, buttocks, or anus. Additional complaints include itching, burning, genital discharge, headache, and muscle pain. Women may also face painful urination and cervical inflammation, while those engaging in anal intercourse can develop herpetic proctitis. Over two to three weeks, active lesions progress through ulceration before crusting and healing, though mucosal sores may skip the crusting stage entirely. In rare instances, the virus can affect the sacral spinal cord, producing urinary retention and one-sided neurological symptoms historically labeled Elsberg syndrome. After the initial episode, roughly 80 percent of HSV-2 carriers and 50 percent of HSV-1 carriers experience at least one recurrence, with HSV-2 causing four to six outbreaks annually versus about one per year for HSV-1.

The Invisible Vector: How the Virus Travels Between Partners

Genital herpes is transmitted through direct contact with infected skin or secretions, a process that can occur during vaginal, anal, oral, or manual sex. Crucially, visible sores are not a prerequisite for spread; the virus sheds from the skin both before and after ulcers form, making asymptomatic transmission a constant risk. For a couple practicing unprotected sex, the annual probability of passing the infection hovers around 7.5 percent, translating to roughly one new case per thousand sexual encounters. The virus comes in two strains, HSV-1 and HSV-2. Although HSV-2 was once the dominant cause of genital infection, HSV-1 has steadily gained ground in the developed world. External and internal condoms each cut transmission risk by about half, and abstaining during an active outbreak further lowers the chance of spread. Interestingly, the longer a partner has carried the infection, the lower the per-act transmission rate becomes. A person taking a daily antiviral medication can also meaningfully reduce the likelihood of passing the virus to a partner, adding another layer of protection beyond barrier methods.

Living With the Virus: Treatment, Suppression, and Complications

Once the herpes simplex virus takes hold in the body, no treatment can eliminate it permanently. Antiviral drugs such as acyclovir, valacyclovir, and famciclovir remain the mainstay of management, either taken episodically to shorten an outbreak or used daily as suppressive therapy for those experiencing four or more recurrences a year. Suppressive regimens are generally reassessed after a maximum of one year to determine whether continued use is warranted. Beyond individual symptom control, daily antivirals offer a powerful public-health benefit: they are approximately 90 percent effective at blocking transmission to sexual or romantic partners, making them a standard recommendation for couples planning a pregnancy. Despite these tools, the virus can occasionally trigger serious complications. Rare cases of aseptic meningitis have been documented, and a person living with genital herpes faces a heightened risk of acquiring HIV if exposed to an HIV-positive partner. Perhaps most alarming is the possibility of the virus crossing to a newborn during delivery, resulting in neonatal herpes, a condition with potentially devastating consequences for the infant.

A Global Footprint: Prevalence, Trends, and the Diagnostic Challenge

By 2015, an estimated 846 million people worldwide, roughly 12 percent of the global population, carried genital herpes. In the United States, more than one in six adults aged 14 to 49 lives with the infection, and women are disproportionately affected compared to men. While HSV-2 rates in the U.S. declined between 1990 and 2010, the global picture tells a different story: cases surged by nearly 52 percent between 1990 and 2021. The steepest increases in prevalence were recorded in South Asia, Southern Sub-Saharan Africa, and Central Europe, with young adults aged 15 to 49 in Southern Sub-Saharan Africa bearing the highest incidence rates of any region. Diagnosis typically relies on PCR or viral culture of lesion fluid, or on blood tests detecting HSV-specific antibodies, and is recommended for symptomatic individuals or those with an infected partner. Because the virus is so widespread and is not routinely screened for in the general population, many infections go undetected, complicating efforts to prevent further transmission and underscoring the need for broader awareness and accessible testing.

Gallery